Study Of Lybrel In Relation To Venous Thromboembolism
Status:
Completed
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
Lybrel® is an oral contraceptive that delivers low doses of levonorgestrel and ethinyl
estradiol (90 μg/20 μg). Lybrel is taken on a continuous basis without a placebo or pill-free
interval to inhibit menstrual cycle bleeding by delivering a steady level of the 2 hormones
for as long as the drug is used. Lybrel was marketed in the US in July of 2007. The objective
of this database case-control study is to estimate the risk of idiopathic VTE (deep vein
thrombosis and pulmonary embolism) in current users of Lybrel (ethinyl estradiol
20ug/levonorgestrel 90ug) compared to current users of other oral contraceptives containing
20μg of ethinyl estradiol.